Scientists hail new prostate cancer drug

Researchers found those who trialled cabazitaxel in the latter, more aggressive stages of the disease, lived on average 30 per cent longer than those taking another medication.

The drug, which has been approved by the US Food and Drug

Administration (FDA), could offer an extra lease of life for thousands of men every year.